Matthew P. Goetz, M.D., a medical oncologist at Mayo Clinic's campus in Rochester, Minnesota, discusses the newest innovations and updates in breast cancer clinical trials. In a recent advancement, Mayo Clinic collaborated with the National Cancer Institute to develop formulations of endoxifen. The drug had substantial anti-tumor activity in women whose cancers had previously progressed on standard hormonal therapy.
Mayo Clinic is increasingly ordering genetic tests on a regular basis for patients, which can substantially help patients with decision-making.
Conditions treated Breast cancer Procedures performed Pharmacogenomic testing Interests Pharmacogenomics of breast cancer Biomarkers of endocrine response Breast cancer drug development in endocrine responsive ...